NDAORALTABLET
Approved
Sep 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
CLINORIL (sulindac) by Merck & Co. is clinical pharmacology pharmacodynamics sulindac is a non-steroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. First approved in 1978.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLINORIL (sulindac) is an oral non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities. It works through inhibition of prostaglandin synthetase, though the exact mechanism is not fully understood. The drug is indicated for patients requiring anti-inflammatory and pain relief therapy.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30 score), indicating team focus should shift toward lifecycle management and cost optimization strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. The mechanism of action, like that of other NSAIDs, is not completely understood but may be related to…
Worked on CLINORIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.